News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mobius Theraputics™ Granted Orphan Drug Designation



1/23/2008 10:07:34 AM

ST. LOUIS, MO--(Marketwire - January 23, 2008) - Mobius Therapeutics, Inc.™ has been granted orphan drug designation for its platform product, Trabomycin™, by the Office of Orphan Products Development of the U.S. Food and Drug Administration. This approval grants seven years of U.S. market exclusivity to Mobius, once its New Drug Application is approved.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES